Feed VYGR
VY

Voyager Therapeutics VYGR · NASDAQ

$1.74 -6.45% (-$0.12)

Market cap
$126.3M
Enterprise value
$123.1M
P/E
-
Forward P/E
-
PEG
-
P/S
3.7x
P/FCF
-
EV/EBITDA
-
ROIC
-62.4%
Gross margin
-104.2%
Net margin
-312.6%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.28
Free float
83.7%

About the company

Voyager Therapeutics, Inc. (VYGR) is a biotechnology company focused on developing therapeutic products for neurological disorders. With a deep understanding of the brain and nervous system, Voyager Therapeutics aims to transform the treatment of these complex diseases through gene therapy. Their research focuses on utilizing adeno-associated viruses to deliver therapeutic genes to the brain and restore normal functions. The company seeks to provide new possibilities for patients with neurodegenerative diseases. Voyager Therapeutics, Inc. (VYGR) shares could be suitable for investors who wish to support innovative developments in treatment approaches within the field of neurology and contribute to improving the quality of life for patients.

Sector

Healthcare

Industry

Biotechnology

CEO

Alfred W. Sandrock Jr.

Employees

141

Headquarters

Lexington

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy